腹腔镜子宫切除术前延长释放布比卡因与短效布比卡因伤口浸润的比较:一项随机对照试验
单中心双盲随机对照试验纳入64例拟行多孔腹腔镜或机器人辅助全子宫切除术的良性指征患者,随机接受切口前未稀释脂质体布比卡因或0.25%布比卡因浸润。主要结局为术后第3天电话调查的简明疼痛量表平均疼痛强度。脂质体布比卡因组术后第3天平均疼痛评分降低(P=0.02),术后第2天(P=0.03)和第3天(P=0.01)最痛评分降低,但住院期间、术后第1天和第14天疼痛评分、疼痛干扰评分、阿片类药物用量及不良反应无差异。
要点
- 脂质体布比卡因组术后第3天平均疼痛评分较0.25%布比卡因组降低(P=0.02)。
- 脂质体布比卡因组术后第2天最痛评分(P=0.03)和术后第3天最痛评分(P=0.01)降低。
- 两组阿片类药物用量、疼痛干扰评分及不良反应无差异。
核心结论
- 对于腹腔镜和机器人辅助多孔子宫切除术,端口部位镇痛使用脂质体布比卡因相比0.25%布比卡因有证据显示可降低术后第3天平均疼痛,但阿片类药物用量或功能测量无差异。
研究设计与样本
- 单中心双盲随机对照试验(加拿大工作组分类I),于一家三级社区医院开展,2015年7月至2016年1月招募患者,64例随机分组,59例纳入主要结局分析。
- 计划每组28例(共56例)以检测疼痛评分30%的变化。
- 患者因良性指征拟行多孔腹腔镜或机器人辅助全子宫切除术,随机接受切口前未稀释脂质体布比卡因或0.25%布比卡因浸润。
主要发现
- 主要结局为术后第3天通过电话调查的简明疼痛量表(BPI)数字评定量表(0-10)总体平均疼痛强度,脂质体布比卡因组平均疼痛评分降低(P=0.02)。
- 脂质体布比卡因组术后第2天最痛评分降低(P=0.03),术后第3天最痛评分降低(P=0.01)。
- 住院期间、术后第1天或术后第14天疼痛评分无差异。
- BPI疼痛干扰评分、阿片类药物用量或报告的不良反应无差异。
- 两组人口学特征无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To evaluate if preincision infiltration with extended-release liposomal bupivacaine provides improved overall pain relief compared with 0.25% bupivacaine after laparoscopic or robotic-assisted hysterectomy. DESIGN: A single-center double-masked randomized controlled trial (Canadian Task Force Classification I). SETTING: A tertiary-care community hospital. PATIENTS: Patients recruited from July 2015 through January 2016. Sixty-four patients were randomized, and 59 were analyzed for the primary outcome. INTERVENTIONS: Women scheduled to undergo multiport laparoscopic or robotic-assisted total hysterectomy for benign indications were randomized to receive preincision infiltration with undiluted liposomal bupivacaine or 0.25% bupivacaine. MEASUREMENTS AND MAIN RESULTS: The primary outcome was overall average pain intensity by numeric rating scale (0-10) using the Brief Pain Inventory (BPI) via telephone survey on postoperative day (POD) 3. A sample size of 28 per group (N = 56) was planned to detect a 30% change in pain scores. Secondary outcomes were overall average and worst numeric pain scores on PODs 1, 2, and 14; pain scores in hospital; BPI pain interference scores; and total opioid use. There were no demographic differences between the 2 groups. For the primary outcome, we found a decrease in the average (p = .02) pain scores on POD 3 in the liposomal bupivacaine group. We also found a decrease in worst pain scores on POD 2 (p = .03) and POD 3 (p = .01). There were no differences in pain scores while in the hospital or on POD 1 or POD 14. There were no differences in BPI pain interference scores, opioid use, or reported adverse effects. CONCLUSION: For laparoscopic and robotic-assisted multiport hysterectomies, there is evidence of decreased average postoperative pain with liposomal bupivacaine compared with 0.25% bupivacaine for port-site analgesia on POD 3, but no difference in opioid use or measures of functioning.
引用
- Barron KI, Lamvu GM, Schmidt RC, et al. Wound Infiltration With Extended-Release Versus Short-Acting Bupivacaine Before Laparoscopic Hysterectomy: A Randomized Controlled Trial. J Minim Invasive Gynecol. 2016. PMID: 27856385. doi:10.1016/j.jmig.2016.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。